ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.92
-0.17 (-1.82%)
▼
5d:
-2.67%
30d:
+5.13%
90d:
-8.09%
BUY
HIGH Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Smart Money Distribution
None View Scanner →
Strength: 6.1/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ADMA trading at deep discount. Market pricing in -10.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ADMA trading at deep discount. Market pricing in -10.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.08
Based on 13.3% avg growth
INTRINSIC VALUE TODAY
$14.33
37.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.91, which is considered slightly high relative to its 30-day fair value range of $8.22 to $8.98. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.1) compared to its historical average (12.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.23, while resistance sits at $9.33.
Market Sentiment: ADMA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+93.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.23, while resistance sits at $9.33.
Market Sentiment: ADMA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+93.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.22 -
$8.98
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 93.8% below Wall St target ($17.60)
Trading Range Analysis
30-Day Trading Range
$8.22 -
$8.98
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.23
Resistance Level
$9.33
Current Trend
Strong Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.10
Wall Street Target
$17.60
(+93.8%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-10.0% cheaper
PE vs Historical
9.1 vs 12.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.0%
(market-implied from PE analysis)
1-Year Target
$8.17
(-10%)
2-Year Target
$7.35
(-19%)
3-Year Target
$6.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→13)
$9.09
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.6%)
$40.08
(+341%)
Base:
(SPY PE: 9.1, Growth: 22.6%)
$16.75
(+85%)
Bear:
(PE: 7.7, Growth: 22.6%)
$14.24
(+57%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.63 | Current EPS (TTM): $0.68
Bull Case
$14.96
(+65%)
Analyst growth 46.7%, PE expands to 15.0
Base Case
$13.60
(+50%)
Market implied 46.7%, PE stable at 13.6
Bear Case
$6.30
(-31%)
Severe decline -20.0%, PE contracts to 11.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.1 to 12.5
Stabilization Target:
$12.47
(+37.3%)
PE Expansion Potential:
+37.3%
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 58 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$200 | 65 BUY |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
